title: Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.
abstract: OBJECTIVE
  The objective was to determine the toxicity and surgically documented response rate of sequential high-dose chemotherapy with peripheral stem cell support in patients with persistent or recurrent cisplatin-sensitive ovarian cancer.
  
  
  METHODS
  Fourteen patients (average age, 45 years) were treated with cyclophosphamide (4.5 g/m2), followed by granulocyte colony-stimulating factor (G-CSF)-stimulated peripheral stem cell harvests. The subsequent regimen prescribed three courses of carboplatin (1 g/m2) and cyclophosphamide (1.5 g/m2 with 2-mercaptoethanesulfonate) every 2 weeks with stem cell support. This was followed by three courses of paclitaxel at 250 mg/m2 every 2 weeks with G-CSF support only. Six patients were entered on the basis of a positive second-look laparotomy and 8 patients had a first recurrence after at least a 6-month disease-free interval.
  
  
  RESULTS
  Fourteen patients were entered and 12 patients completed all planned courses of therapy (mean time, 13 weeks). Normal hematopoiesis was reestablished after each cycle. Hospitalization for neutropenic fever occurred in 11/93 cycles (11.8%). Thirteen patients required blood transfusions and in 12 patients platelet transfusions were given. One patient had grade 3 neurotoxicity. An initial elevated CA 125 returned to normal in 7/8 patients (88%) and 71% of patients with measurable disease responded to therapy. There were 2 pathologic complete responders (PCR), making the PCR rate 2/14 or 14% (0-35%).
  
  
  CONCLUSIONS
  Although this regimen was well tolerated and clinical response rates were high, the surgically documented response rate was not clearly superior to conventional salvage regimens in platinum-sensitive patients.
authors.affiliation: Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Medical Center, Philadelphia 19104, USA. mmorgan_onco@obgyn.upenn.edu
authors.forename: M A
authors.initials: MA
authors.lastname: Morgan
authors.forename: E A
authors.initials: EA
authors.lastname: Stadtmauer
authors.forename: S M
authors.initials: SM
authors.lastname: Luger
authors.forename: D L
authors.initials: DL
authors.lastname: Porter
authors.forename: P A
authors.initials: PA
authors.lastname: Mangan
authors.forename: P
authors.initials: P
authors.lastname: O'Neil
authors.forename: S
authors.initials: S
authors.lastname: Kamelle
authors.forename: I
authors.initials: I
authors.lastname: Benjamin
authors.forename: R
authors.initials: R
authors.lastname: Mick
authors.forename: S A
authors.initials: SA
authors.lastname: King
authors.forename: S C
authors.initials: SC
authors.lastname: Rubin
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D003520:Cyclophosphamide; D016190:Carboplatin; D017239:Paclitaxel